Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
You may also be interested in...
Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.
Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.